A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
Portfolio Pulse from Benzinga Newsdesk
CytoMed Therapeutics Limited (NASDAQ:GDTC), a Singapore-based biopharmaceutical company, has been granted a patent by the US Patent and Trademark Office for its CAR-gamma delta T cell technology, which it has exclusively licensed from A*STAR.

July 06, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The granting of the patent for its CAR-gamma delta T cell technology could potentially boost CytoMed Therapeutics' market position and increase its stock value.
The granting of a patent is a significant milestone for any company, especially for a biopharmaceutical company like CytoMed Therapeutics. This could potentially lead to an increase in its stock value as it strengthens the company's market position and protects its technology from being copied by competitors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100